PURPOSE: To establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and pharmacokinetic profile of ispinesib when administered as a 1-h intravenous infusion weekly for three consecutive weeks of a 28 day treatment period to patients with advanced solid tumors. EXPERIMENTAL DESIGN: Thirty patients were enrolled using an initial accelerated dose-escalation phase followed by a standard dose-escalation phase at doses ranging from 1-8 mg/m(2)/week. Pharmacokinetic samples, skin punch biopsies, and tumor biopsies (in patients with accessible tumor) were obtained during cycle 1 of treatment. Disease assessment was performed every two treatment cycles. RESULTS: The MTD was defined as 7 mg/m(2) administered as a 1-h infusion weekly for three consecutive weeks of a 28 day schedule. The MTD was exceeded at 8 mg/m(2) due to DLTs of grade 2 (one patient) and grade 3 neutropenia (one patient) that resulted in the inability to administer the Day 15 dose in Cycle 1. The neutrophil nadir occurred at approximately Day 8 with a 3-7 day recovery period. The most common toxicities were nausea, diarrhea, fatigue, and neutropenia. Alopecia, mucositis, and neuropathy were not observed. Stable disease was reported as the best response to treatment in nine patients. CONCLUSION: The recommended dose of ispinesib is 7 mg/m(2) over 1 h weekly for three consecutive weeks of a 28 day treatment cycle.
PURPOSE: To establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and pharmacokinetic profile of ispinesib when administered as a 1-h intravenous infusion weekly for three consecutive weeks of a 28 day treatment period to patients with advanced solid tumors. EXPERIMENTAL DESIGN: Thirty patients were enrolled using an initial accelerated dose-escalation phase followed by a standard dose-escalation phase at doses ranging from 1-8 mg/m(2)/week. Pharmacokinetic samples, skin punch biopsies, and tumor biopsies (in patients with accessible tumor) were obtained during cycle 1 of treatment. Disease assessment was performed every two treatment cycles. RESULTS: The MTD was defined as 7 mg/m(2) administered as a 1-h infusion weekly for three consecutive weeks of a 28 day schedule. The MTD was exceeded at 8 mg/m(2) due to DLTs of grade 2 (one patient) and grade 3 neutropenia (one patient) that resulted in the inability to administer the Day 15 dose in Cycle 1. The neutrophil nadir occurred at approximately Day 8 with a 3-7 day recovery period. The most common toxicities were nausea, diarrhea, fatigue, and neutropenia. Alopecia, mucositis, and neuropathy were not observed. Stable disease was reported as the best response to treatment in nine patients. CONCLUSION: The recommended dose of ispinesib is 7 mg/m(2) over 1 h weekly for three consecutive weeks of a 28 day treatment cycle.
Authors: Lukas C Kapitein; Erwin J G Peterman; Benjamin H Kwok; Jeffrey H Kim; Tarun M Kapoor; Christoph F Schmidt Journal: Nature Date: 2005-05-05 Impact factor: 49.962
Authors: Weikang Tao; Victoria J South; Ronald E Diehl; Joseph P Davide; Laura Sepp-Lorenzino; Mark E Fraley; Kenneth L Arrington; Robert B Lobell Journal: Mol Cell Biol Date: 2006-11-13 Impact factor: 4.272
Authors: Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour Journal: Invest New Drugs Date: 2007-10-26 Impact factor: 3.850
Authors: Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steve Weitman; Kenneth W Wood Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: S P Blagden; L R Molife; A Seebaran; M Payne; A H M Reid; A S Protheroe; L S Vasist; D D Williams; C Bowen; S J Kathman; J P Hodge; M M Dar; J S de Bono; M R Middleton Journal: Br J Cancer Date: 2008-03-04 Impact factor: 7.640
Authors: Shrikanta Chattopadhyay; Alison L Stewart; Siddhartha Mukherjee; Cherrie Huang; Kimberly A Hartwell; Peter G Miller; Radhika Subramanian; Leigh C Carmody; Rushdia Z Yusuf; David B Sykes; Joshiawa Paulk; Amedeo Vetere; Sonia Vallet; Loredana Santo; Diana D Cirstea; Teru Hideshima; Vlado Dančík; Max M Majireck; Mahmud M Hussain; Shambhavi Singh; Ryan Quiroz; Jonathan Iaconelli; Rakesh Karmacharya; Nicola J Tolliday; Paul A Clemons; Malcolm A S Moore; Andrew M Stern; Alykhan F Shamji; Benjamin L Ebert; Todd R Golub; Noopur S Raje; David T Scadden; Stuart L Schreiber Journal: Cell Rep Date: 2015-02-05 Impact factor: 9.423
Authors: Hung Yi Kristal Kaan; Jennifer Major; Katarzyna Tkocz; Frank Kozielski; Steven S Rosenfeld Journal: J Biol Chem Date: 2013-05-08 Impact factor: 5.157
Authors: John F Gerecitano; Joe J Stephenson; Nancy L Lewis; Anna Osmukhina; Jianguo Li; Kaida Wu; Zhiping You; Dennis Huszar; Jeffrey M Skolnik; Gary K Schwartz Journal: Invest New Drugs Date: 2012-05-22 Impact factor: 3.850
Authors: Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim Journal: Gene Date: 2013-08-14 Impact factor: 3.688
Authors: A Hollebecque; E Deutsch; C Massard; C Gomez-Roca; R Bahleda; V Ribrag; C Bourgier; V Lazar; L Lacroix; A Gazzah; A Varga; T de Baere; F Beier; S Kroesser; K Trang; F T Zenke; M Klevesath; Jean-Charles Soria Journal: Invest New Drugs Date: 2013-12 Impact factor: 3.850